The following is a link to an interview with Dr Tian Zhang, a medical instructor in the Department of Medicine, Duke University School of Medicine, by OncLive at the 2016 Kidney Cancer Symposium, in which Dr Zhang discusses the challenges associated with vaccine development in kidney cancer and the hope that vaccines can still be the answer to improving the response rates with anti-PD-1/PD-L1 treatment in renal cell carcinoma (RCC).
Hope that vaccines may improve immunotherapy outcomes in kidney cancer
25 Jan 2017
Most used tags
renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib Sutent progression-free survival cabozantinib biomarkers NHS England Cabometyx ipilimumab COVID-19 pembrolizumab cancer survival axitinib VEGF inhibitors non-clear cell kidney cancer Inlyta coronavirus Yervoy risk factors Keytruda metastases adjuvant therapy biological markers targeted therapy papillary RCC everolimus Afinitor ASCO cancer outcomes first-line treatment NICE partial nephrectomyArchives
- 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec